Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium Y 90 monoclonal antibody B3
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Yttrium Y 90 monoclonal antibody B3 is a radiolabeled murine monoclonal antibody targeting the LewisY carbohydrate antigen, which is expressed on the surface of many epithelial carcinomas. The drug consists of the murine mAb B3 conjugated to the beta-emitting radioisotope yttrium-90 (Y-90), enabling targeted radioimmunotherapy. Upon administration, the antibody binds to LewisY-expressing tumor cells and delivers localized radiation via Y-90 decay, aiming to destroy malignant cells while sparing normal tissue. Phase I clinical trials have demonstrated tumor localization and established myelosuppression as a dose-limiting toxicity. Humanized versions are under development for further evaluation in cancer therapy[1][4].
- Other names
- yttrium Y 90 monoclonal antibody B390Y-labeled MoAb B3radioimmunoconjugate of MoAb B3 with Yttrium-90
02
Targets
LeY (Lewis Y antigen)
Beyond the preview
Go deeper on yttrium Y 90 monoclonal antibody B3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium Y 90 monoclonal antibody B3.